Fig. 1From: Pegylated liposomal doxorubicin in patients with epithelial ovarian cancerThe clinical trial profile. C, cycle; D, day; PLD, pegylated liposomal doxorubicin; RECIST 1.1, the Response Evaluation Criteria in Solid Tumors version 1.1; GCIG, Gynecologic Cancer InterGroupBack to article page